Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benedikt Pulver

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
International Journal of Legal Medicine|October 20, 2025
Fatal intoxication involving amphetamine, clonazafone, a benzodiazepine prodrug, and fluoro-etonitazene, a new synthetic opioidJonas Malzacher, Benedikt Pulver, Nicolas Heller, et al.
Data in Brief|January 6, 2022
Dataset allowing for the identification of three new synthetic cannabimimetics featuring a norbornyl methyl side chain by spectrometric and spectroscopic techniquesBenedikt Pulver, Jan Riedel, Torsten Schönberger, et al.
Drug Testing and Analysis|March 31, 2021
New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl-CBMICA and Cumyl-CBMINACABelal Haschimi, Katharina Elisabeth Grafinger, Benedikt Pulver, et al.
Drug Testing and Analysis|June 15, 2023
Analytical and behavioral characterization of N-ethyl-N-isopropyllysergamide (EIPLA), an isomer of N<sup>6</sup> -ethylnorlysergic acid N,N-diethylamide (ETH-LAD)Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Drug Testing and Analysis|May 7, 2022
Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LADSimon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Archives of Toxicology|October 31, 2025
Human metabolism and pharmacological profiling of protonitazepyne and metonitazepyne, two highly potent nitazenes: prediction of main metabolite activity based on µ-opioid receptor docking simulationsDiletta Berardinelli, Omayema Taoussi, Duygu Yeşim Ovat, et al.
Drug Testing and Analysis|October 10, 2020
Cumyl-CBMICA: A new synthetic cannabinoid receptor agonist containing a cyclobutyl methyl side chainSebastian Halter, Benedikt Pulver, Maurice Wilde, et al.
Drug Testing and Analysis|November 2, 2022
Analytical profile of the lysergamide 1cP-AL-LAD and detection of impuritiesPierce V Kavanagh, Folker Westphal, Benedikt Pulver, et al.
Journal of Pharmaceutical and Biomedical Analysis|May 1, 2024
Metabolism and cytotoxicity studies of the two hallucinogens 1cP-LSD and 4-AcO-DET in human liver and zebrafish larvae models using LC-HRMS/MS and a high-content screening assayTanja M Gampfer, Victoria Schütz, Philip Schippers, et al.
Drug Testing and Analysis|December 21, 2022
Pharmacology, prevalence in Germany, and analytical data of cyclobutylmethyl- and norbornylmethyl-type synthetic cannabinoid receptor agonistsBenedikt Pulver, Jan Riedel, Torsten Schönberger, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
International Journal of Legal Medicine|October 20, 2025
Fatal intoxication involving amphetamine, clonazafone, a benzodiazepine prodrug, and fluoro-etonitazene, a new synthetic opioidJonas Malzacher, Benedikt Pulver, Nicolas Heller, et al.
Data in Brief|January 6, 2022
Dataset allowing for the identification of three new synthetic cannabimimetics featuring a norbornyl methyl side chain by spectrometric and spectroscopic techniquesBenedikt Pulver, Jan Riedel, Torsten Schönberger, et al.
Drug Testing and Analysis|March 31, 2021
New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl-CBMICA and Cumyl-CBMINACABelal Haschimi, Katharina Elisabeth Grafinger, Benedikt Pulver, et al.
Drug Testing and Analysis|June 15, 2023
Analytical and behavioral characterization of N-ethyl-N-isopropyllysergamide (EIPLA), an isomer of N<sup>6</sup> -ethylnorlysergic acid N,N-diethylamide (ETH-LAD)Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Drug Testing and Analysis|May 7, 2022
Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LADSimon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Archives of Toxicology|October 31, 2025
Human metabolism and pharmacological profiling of protonitazepyne and metonitazepyne, two highly potent nitazenes: prediction of main metabolite activity based on µ-opioid receptor docking simulationsDiletta Berardinelli, Omayema Taoussi, Duygu Yeşim Ovat, et al.
Drug Testing and Analysis|October 10, 2020
Cumyl-CBMICA: A new synthetic cannabinoid receptor agonist containing a cyclobutyl methyl side chainSebastian Halter, Benedikt Pulver, Maurice Wilde, et al.
Drug Testing and Analysis|November 2, 2022
Analytical profile of the lysergamide 1cP-AL-LAD and detection of impuritiesPierce V Kavanagh, Folker Westphal, Benedikt Pulver, et al.
Journal of Pharmaceutical and Biomedical Analysis|May 1, 2024
Metabolism and cytotoxicity studies of the two hallucinogens 1cP-LSD and 4-AcO-DET in human liver and zebrafish larvae models using LC-HRMS/MS and a high-content screening assayTanja M Gampfer, Victoria Schütz, Philip Schippers, et al.
Drug Testing and Analysis|December 21, 2022
Pharmacology, prevalence in Germany, and analytical data of cyclobutylmethyl- and norbornylmethyl-type synthetic cannabinoid receptor agonistsBenedikt Pulver, Jan Riedel, Torsten Schönberger, et al.
Pageof 3